Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068831 · ClinicalTrials.gov registry record · Phase 2
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
A Phase 2 study of Metastatic Renal Cell Carcinoma and Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT04068831: Completed Phase 2 study of Metastatic Renal Cell Carcinoma and Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04068831 is a Phase 2 study of Metastatic Renal Cell Carcinoma and Succinate Dehydrogenase-Deficient Renal Cell Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants, below the 143-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04068831, a Phase 2 study of Metastatic Renal Cell Carcinoma and Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
Primary Outcome
confirmed complete response (iCR) or partial response (iPR) assessed by iRECIST.
Conditions Studied
Interventions
- DRUG Talazoparib
- DRUG Avelumab
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2023-12-06 |
| Phase | Phase 2 |
What the finished NCT04068831 record still lists
NCT04068831 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 143-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.
NCT04068831 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04068831 about?
NCT04068831 is a clinical study titled "Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma". The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
What is the current status of trial NCT04068831?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-08-22. Estimated completion is 2023-12-06.
What conditions does trial NCT04068831 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma, Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma.
What interventions are being tested in trial NCT04068831?
The interventions under investigation include: Talazoparib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT04068831?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04068831 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04068831's enrollment target sits among peer trials
18 34th of 37 higher than 3 of 37 other Metastatic Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI